Formulary guidance and transparency from P&T to point of care

MMIT Reality Check on Cystic Fibrosis (Jan 2018)

Posted by Matt Breese on Jan 23, 2018

Find me on:

According to our recent payer coverage analysis for CF treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT's team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Payer Coverage: A review of market access for payer pharmacy benefit formularies reveals an increase in restricted lives covered under medicare plans. However, we also saw a reduction in the overall percentage of covered lives restricted by a PA or step edit policy.


Source: MMIT data as of Q1 2018

Trends: Cystic fibrosis transmembrane conductance regulators (CFTR) modulators refocus care approaches with the goal of treating the disease, rather than simply addressing symptoms. Over the next five years, several new market entrants are expected to offset the effects of key patent losses.

To read the full Reality Check on cystic fibrosis with key findings on clinical characteristics, CF drug market access and payer coverage, please click on the thumbnail below: 


View Reality Check

Topics: Specialty, Market Access, Branding & Marketing